Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-04-22 00:00:00 ET · period of report 2022-04-20 · accession 0000899243-22-015393 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-22 | 2022-04-20 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $6.68 | -852 | 404.8K | -0.2% | -$5,691 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-20 | S | D | 852 | $6.68 | 404,788 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.665 to $6.6976. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |